ATC code J02 Antimycotics for systemic use is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.[1][2][3] Subgroup J02 is part of the anatomical group J Antiinfectives for systemic use.[4]
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QJ02.[5] ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list.
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
J02A Antimycotics for systemic use
editJ02AA Antibiotics
edit- J02AA01 Amphotericin B
- J02AA02 Hachimycin
- J02AB01 Miconazole
- J02AB02 Ketoconazole
- QJ02AB90 Clotrimazole
- J02AC01 Fluconazole
- J02AC02 Itraconazole
- J02AC03 Voriconazole
- J02AC04 Posaconazole
- J02AC05 Isavuconazole
- J02AC06 Oteseconazole
J02AX Other antimycotics for systemic use
edit- J02AX01 Flucytosine
- J02AX04 Caspofungin
- J02AX05 Micafungin
- J02AX06 Anidulafungin
- J02AX07 Ibrexafungerp
- J02AX08 Rezafungin acetate
References
edit- ^ "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020.
- ^ World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.
- ^ "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.
- ^ "ATC/DDD Index 2022: code J02". WHO Collaborating Centre for Drug Statistics Methodology.
- ^ "ATCvet Index 2022: code QJ02". WHO Collaborating Centre for Drug Statistics Methodology.